Articles tagged "Immunosuppression"

2022 American Transplant Congress
Thymoglobulin Induction Protocol: Quality Improvement Project via Clinical Audit
S. Mouawad¹, J. Dann¹, A. Kumar², S. Rao³
¹University of Virginia Health System, Charlottesville, VA, ²Nephrology, University of Virginia, Charlottesville, VA, ³University of Virginia, Charlottesville, VA
*Purpose: The aim of our study was to analyze the adequacy of the thymoglobulin (rATG) induction protocol for the expanding and higher complexity kidney transplant…
2022 American Transplant Congress
Comparing Long-Term Outcomes of Steroid-Based versus Steroid-Avoidant Immunosuppression in Pediatric Kidney Transplant Recipients
N. Hayde¹, E. Blanchette², J. Zhang³, M. Chandran², M. Bock², S. Galbiati³, T. Blydt-Hansen⁴
¹Montefiore Medical Center, Bronx, NY, ²Children's Hospital Colorado, Aurora, CO, ³Emmes Corporation, Rockville, MD, ⁴University of British Columbia, Vancouver, BC, Canada
*Purpose: With increasing use of potent immunosuppressant (IS) medications, steroid-avoidant (SA) regimens are now commonly used for pediatric kidney transplant recipients (pKTs) to avoid potential…
2022 American Transplant Congress
Case-Control Study of Belatacept as Maintenance Immunosuppression in Kidney Transplant Recipients Living with HIV
M. Tucker, C. Foppiano Palacios, E. Cohen, S. Virmani, P. Trubin, L. A-Barakat, M. M. Azar, M. Malinis
Yale School of Medicine, New Haven, CT
*Purpose: Belatacept has been increasingly used in kidney transplant recipients (KTR) as a calcineurin-inhibitor (CNI) sparing agent. There are little data on belatacept use in…
2022 American Transplant Congress
Everolimus versus Mycophenolate in Simultaneous Pancreas and Kidney Transplantation: Progression of Diabetic Retinopathy in a Prospective Randomized Trial
B. Hagerf¹, Z. Hladíková¹, M. Zahradnická¹, K. Kesslerová², T. Sosna², P. Girman¹, F. Saudek¹
¹Diabetes Centre, IKEM, Prague, Czech Republic, ²Ophtalmology Clinic, Thomayer Hospital, Prague, Czech Republic
*Purpose: mTOR inhibitors are known for their antiangiogenic effect. We compared the impact of everolimus (E) and mycophenolic acid (MPA) on the course of diabetic…
2022 American Transplant Congress
Belatacept Conversion in Proteinuric Kidney Transplant Recipients: Effects in a Prospective Trial and a Retrospective Cohort
O. Efe¹, A. Al Jurdi¹, D. Wojciechowski², K. Safa¹, H. Gilligan¹, A. Chandraker³, J. Azzi³, A. Weins³, L. V. Riella¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, ²UT Southwestern Medical Center, Dallas, TX, ³Brigham and Women's Hospital, Boston, MA
*Purpose: Proteinuria after kidney transplantation is associated with worse allograft outcomes. B7-1 expression by podocytes has been linked to proteinuria by inducing podocyte migration which…
2022 American Transplant Congress
A Novel Immunosuppressive Compound (79-6) That Targets Bcl6 Prevents the Humoral Alloresponse
R. Kraaijeveld, D. A. Hesselink, C. C. Baan
Internal medicine - Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, Netherlands
*Purpose: BCL6, is a transcription factor involved in B cell activation and differentiation. BCL6-expressing B cells play a crucial role in the development and maintenance…
2022 American Transplant Congress
Immunomodulation in Lung Transplant May Facilitate Transformation of Usual Interstitial Pneumonia Into Pleuroparenchymal Fibroelastosis
Q. Cai¹, K. Batra², J. R. Torrealba¹
¹Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare but distinctive manifestation of interstitial lung disease (ILD) characterized by a highly elastotic pattern of lung fibrosis. Its…
2022 American Transplant Congress
Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial
A. Zarrinpar¹, C. Ho², C. Warren¹, J. Khong², M. Lee², S. Duarte¹, K. Andreoni¹, M. Johnson¹, N. Battula³, D. McKimmy¹, T. Beduschi¹
¹Surgery, University of Florida, Gainesville, FL, ²Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, ³Surgery, University of Oklahoma, Oklahoma City, OK
*Purpose: Inter- and intra-individual variability in calcineurin dose requirements necessitates empirical clinician-titrated dosing that frequently results in deviation from target ranges, particularly during the critical…
2022 American Transplant Congress
Clinically Available Immunosuppressive Agents Prolong Pig-to-Primate Kidney Xenograft Survival
I. J. Anwar¹, Q. Gao¹, I. DeLaura¹, J. Yoon¹, R. Baldi¹, M. Youd², K. Stiede², K. Hall², S. Knechtle¹, J. Kwun¹
¹Surgery, Duke Transplant Center, Durham, NC, ²eGenesis Inc, Cambridge, MA
*Purpose: Most immunosuppressive regimens used in Pig-To-Primate Xenotransplantation contain anti-CD154 agents, compounds that are currently not FDA-approved. The aim of this study was to assess…
2022 American Transplant Congress
Long Term Longitudinal TTV Measurements in Lung Transplant Recipients
E. Gore¹, C. Rondaan¹, E. A. Verschuuren², L. Gard¹, H. G. Niesters¹, C. van Leer-Buter¹
¹Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ²Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
*Purpose: To investigate how levels of Torque Teno Virus (TTV), a virus which has been proposed as a marker for immunosuppression change over a period…